

CLAIMS

*A3d*

*A3*

1 A composition for use in the treatment of hepatocellular carcinoma comprising, as active ingredient, docetaxel or a hydrate thereof.

2. A composition according to claim 1, wherein the hydrate is the trihydrate.

5 3. A composition according to claim 1 or 2, which is for parenteral administration.

4. A composition according to claim 3, which is suitable for intraperitoneal, subcutaneous, intravenous, intramuscular or intrasternal administration and contains from 38 to 42 mg/ml of active compound.

10 5. A composition according to claim 3, which is suitable for administration by infusion and contains from 0.1 to 11 mg/ml of active compound.

2025 RELEASE UNDER E.O. 14176